Rebecca Dent1,2, Mafalda Oliveira3, Steven J Isakoff4, Seock-Ah Im5, Marc Espié6, Sibel Blau7, Antoinette R Tan8, Cristina Saura3, Matthew J Wongchenko9, Na Xu10, Denise Bradley11, Sarah-Jayne Reilly11, Aruna Mani12, Sung-Bae Kim13. 1. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. rebecca.dent@duke-nus.edu.sg. 2. Duke-NUS Medical School, 11 Hospital Crescent, Singapore, Singapore. rebecca.dent@duke-nus.edu.sg. 3. Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 4. Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA. 5. Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Medical Oncology, Breast Disease Center, Hospital Saint Louis, Paris, France. 7. Oncology Division, Northwest Medical Specialties, Puyallup, WA, USA. 8. Department of Solid Tumor and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. 9. Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. 10. Biostatistics, Genentech, Inc., South San Francisco, CA, USA. 11. Pharma Development, Roche Products Ltd, Welwyn Garden City, UK. 12. Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA. 13. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Abstract
PURPOSE: In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors (FoundationOne next-generation sequencing [NGS] assay). We report final overall survival (OS) results. METHODS:Eligible patients had measurable previously untreated aTNBC. Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free interval, and tumor immunohistochemistry PTEN status, and were randomized 1:1 to paclitaxel 80 mg/m2 (days 1, 8, 15) plus ipatasertib 400 mg or placebo (days 1-21) every 28 days until disease progression or unacceptable toxicity. OS (intent-to-treat [ITT], immunohistochemistry PTEN-low, and PI3K/AKT pathway-activated [NGS PIK3CA/AKT1/PTEN-altered] populations) was a secondary endpoint. RESULTS: Median follow-up was 19.0 versus 16.0 months in the ipatasertib-paclitaxel versus placebo-paclitaxel arms, respectively. In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%). Likewise, median OS favored ipatasertib-paclitaxel in the PTEN-low (n = 48; 23.1 vs 15.8 months; hazard ratio 0.83) and PIK3CA/AKT1/PTEN-altered (n = 42; 25.8 vs 22.1 months; hazard ratio 1.13) subgroups. The ipatasertib-paclitaxel safety profile was unchanged. CONCLUSIONS: Final OS results show a numerical trend favoring ipatasertib-paclitaxel and median OS exceeding 2 years with ipatasertib-paclitaxel. Overall, results are consistent with the reported PFS benefit; interpretation within biomarker-defined subgroups is complicated by small sample sizes and TNBC heterogeneity.
RCT Entities:
PURPOSE: In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors (FoundationOne next-generation sequencing [NGS] assay). We report final overall survival (OS) results. METHODS: Eligible patients had measurable previously untreated aTNBC. Patients were stratified by prior (neo)adjuvant therapy, chemotherapy-free interval, and tumor immunohistochemistry PTEN status, and were randomized 1:1 to paclitaxel 80 mg/m2 (days 1, 8, 15) plus ipatasertib 400 mg or placebo (days 1-21) every 28 days until disease progression or unacceptable toxicity. OS (intent-to-treat [ITT], immunohistochemistry PTEN-low, and PI3K/AKT pathway-activated [NGS PIK3CA/AKT1/PTEN-altered] populations) was a secondary endpoint. RESULTS: Median follow-up was 19.0 versus 16.0 months in the ipatasertib-paclitaxel versus placebo-paclitaxel arms, respectively. In the ITT population (n = 124), median OS was numerically longer with ipatasertib-paclitaxel than placebo-paclitaxel (hazard ratio 0.80, 95% CI 0.50-1.28; median 25.8 vs 16.9 months, respectively; 1-year OS 83% vs 68%). Likewise, median OS favored ipatasertib-paclitaxel in the PTEN-low (n = 48; 23.1 vs 15.8 months; hazard ratio 0.83) and PIK3CA/AKT1/PTEN-altered (n = 42; 25.8 vs 22.1 months; hazard ratio 1.13) subgroups. The ipatasertib-paclitaxel safety profile was unchanged. CONCLUSIONS: Final OS results show a numerical trend favoring ipatasertib-paclitaxel and median OS exceeding 2 years with ipatasertib-paclitaxel. Overall, results are consistent with the reported PFS benefit; interpretation within biomarker-defined subgroups is complicated by small sample sizes and TNBC heterogeneity.
Authors: James F Blake; Rui Xu; Josef R Bencsik; Dengming Xiao; Nicholas C Kallan; Stephen Schlachter; Ian S Mitchell; Keith L Spencer; Anna L Banka; Eli M Wallace; Susan L Gloor; Matthew Martinson; Richard D Woessner; Guy P A Vigers; Barbara J Brandhuber; Jun Liang; Brian S Safina; Jun Li; Birong Zhang; Christine Chabot; Steven Do; Leslie Lee; Jason Oeh; Deepak Sampath; Brian B Lee; Kui Lin; Bianca M Liederer; Nicholas J Skelton Journal: J Med Chem Date: 2012-09-18 Impact factor: 7.446
Authors: Timothy A Yap; Michelle D Garrett; Mike I Walton; Florence Raynaud; Johann S de Bono; Paul Workman Journal: Curr Opin Pharmacol Date: 2008-08-27 Impact factor: 5.547
Authors: Kamal Pandey; Hee-Jung An; Seung Ki Kim; Seung Ah Lee; Sewha Kim; Sun Min Lim; Gun Min Kim; Joohyuk Sohn; Yong Wha Moon Journal: Int J Cancer Date: 2019-01-07 Impact factor: 7.396
Authors: Julia Hörnschemeyer; Timo Kirschstein; Gesine Reichart; Christin Sasse; Jakob Venus; Anne Einsle; Katrin Porath; Michael Linnebacher; Rüdiger Köhling; Falko Lange Journal: Life (Basel) Date: 2022-08-17